Despite strong revenue growth, Baxter struggles with profitability and high long-term debt. Click here to read why BAX stock ...

Baxter International’s longtime CEO and board chair, José Almeida, is stepping down and retiring, effective immediately, the ...

These capital equipment offerings, along with Baxter's own infusion pumps, were negatively affected by inflationary pressures on input costs in the difficult 2022-23 period. We see these product ...

Baxter might have faced fourth-quarter hurdles from Hurricane Helene. However, it expects growth in infusion therapies, ...

Baxter's Q3 beat was driven by strong demand for Medical Products & Therapies, including the successful U.S. launch of the Novum IQ infusion pump. For fiscal 2024, analysts expect BAX to report ...

IV treatment is one of the most traditionalist and wide-spread treatments provided to the 90% of hospitalised patients, yet, recent supply challenges like the Baxter IV fluids crisis have shown ...

MRI-Compatible IV Infusion Pump Systems MarketThe global market for MRI-compatible IV infusion pump systems is set for significant expansion, driven by advancements in medical imaging and increasing ...